TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial

Matthew B Laurens, Randy G Mungwira, Osward M Nyirenda, Titus H Divala, Maxwell Kanjala, Francis Muwalo, Felix A Mkandawire, Lufina Tsirizani, Wongani Nyangulu, Edson Mwinjiwa, Terrie E Taylor, Jane Mallewa, William C Blackwelder, Christopher V Plowe, Miriam K Laufer, Joep J van Oosterhout, Matthew B Laurens, Randy G Mungwira, Osward M Nyirenda, Titus H Divala, Maxwell Kanjala, Francis Muwalo, Felix A Mkandawire, Lufina Tsirizani, Wongani Nyangulu, Edson Mwinjiwa, Terrie E Taylor, Jane Mallewa, William C Blackwelder, Christopher V Plowe, Miriam K Laufer, Joep J van Oosterhout

Abstract

Background: Before antiretroviral therapy (ART) became widely available in sub-Saharan Africa, several studies demonstrated that daily trimethoprim-sulfamethoxazole (TS) prophylaxis reduced morbidity and mortality among HIV-infected adults. As a result, the World Health Organization (WHO) recommended administering TS prophylaxis to this group. However, the applicability of the results to individuals taking ART and living in sub-Saharan Africa has not been definitively evaluated. This study aims to determine if TS prophylaxis benefits HIV-infected Malawian adults after a good response to ART. If TS prophylaxis does indeed show benefit, it is important to determine if this is due to its antibacterial and/or antimalarial properties.

Methods/design: A randomized, controlled, open-label, phase III trial of continued standard of care prophylaxis with daily trimethoprim-sulfamethoxazole (TS) compared to discontinuation of standard of care TS prophylaxis and starting weekly chloroquine (CQ) prophylaxis or discontinuation of standard of care TS prophylaxis. The study will randomize 1400-1500 HIV-infected adults (equally divided over the three study arms) with a nondetectable viral load and a CD4 count of 250/mm(3) or more from antiretroviral therapy clinics in Blantyre and Zomba. The expected rate of primary endpoint events of death and WHO stage 3 and 4 events is 6.8 per 100 person-years of follow-up in all participants. Assuming the number of events follows a Poisson distribution and average participant follow-up after 10 % loss to follow-up is 41.6 months, the study will have approximately 85 % power to rule out a reduction of 35 % or more in primary endpoint events in the TS or CQ arms compared to discontinuation of TS prophylaxis-i.e., to show that discontinuation of TS prophylaxis is noninferior to either TS or CQ, with a noninferiority margin of 35 %. Ethical and regulatory approvals were obtained from the University of Malawi College of Medicine Research Ethics Committee; the Malawi Pharmacy, Medicines and Poisons Board; and the University of Maryland Baltimore Institutional Review Board.

Discussion: The study began recruitment activities at the Ndirande site in November 2012. The sponsor agreed to extend and expand the study in early 2015, and a second site, Zomba, was added for recruitment and follow-up in mid-2015.

Trial registration: ClinicalTrials.gov Identifier: NCT01650558 (registered on 6 July 2012).

Protocol version: Letter of amendment #1 to the DAIDS-ES 10822 TSCQ Malawi Protocol, Version 4.0, 16 December 2014.

Keywords: Adult; Africa; Antiretroviral therapy; Chloroquine; HIV infection; Immunosuppression; Longitudinal studies; Malaria; Malawi; Parasitemia; Plasmodium falciparum; Trimethoprim-sulfamethoxazole.

Figures

Fig. 1
Fig. 1
Trial flow diagram

References

    1. Anglaret X, Chêne G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d’Ivoire: a randomised trial. Lancet. 1999;353(9163):1463–8. doi: 10.1016/S0140-6736(98)07399-1.
    1. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d’Ivoire: a randomised controlled trial. Lancet. 1999;353(9163):1469–75. doi: 10.1016/S0140-6736(99)03465-0.
    1. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004;364(9443):1428–34. doi: 10.1016/S0140-6736(04)17225-5.
    1. Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet. 2004;364(9448):1865–71. doi: 10.1016/S0140-6736(04)17442-4.
    1. Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, Morlat P, et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis. 2010;51(5):611–9. doi: 10.1086/655761.
    1. Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, Reid A, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet. 2010;375(9722):1278–86. doi: 10.1016/S0140-6736(10)60057-8.
    1. Campbell JD, Moore D, Degerman R, Kaharuza F, Were W, Muramuzi E, et al. HIV-infected Ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/mm3 who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis. 2012;54(8):1204–11. doi: 10.1093/cid/cis013.
    1. Anywaine Z, Abaasa A, Levin J, Kasiyre R, Kamali A, Grosskurth H, et al. Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design. Contemp Clin Trials. 2015;43:100–4. doi: 10.1016/j.cct.2015.05.015.
    1. Kasirye RP, Baisley K, Munderi P, Levin J, Anywaine Z, Nunn A, et al. Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study. AIDS. 2016;30(4):635–44. doi: 10.1097/QAD.0000000000000956.
    1. Polyak CS, Yuhas K, Singa B, Khaemba M, Walson J, Richardson BA, et al. Cotrimoxazole prophylaxis discontinuation among antiretroviral-treated HIV-1-infected adults in Kenya: a randomized non-inferiority trial. PLoS Med. 2016;13(1):e1001934. doi: 10.1371/journal.pmed.1001934.
    1. Kublin JG, Patnaik P, Jere CS, Miller WC, Hoffman IF, Chimbiya N, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet. 2005;365(9455):233–40.
    1. Ministry of Health Malawi. HIV Unit: Ministry of Health Malawi. 2011 [First].
    1. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. WHO Library Cataloguing-in-Publication Data. 2010.
    1. Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med. 1999;340(17):1301–6. doi: 10.1056/NEJM199904293401701.
    1. Weverling GJ, Mocroft A, Ledergerber B, Kirk O, Gonzales-Lahoz J, d’Arminio Monforte A, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet. 1999;353(9161):1293–8. doi: 10.1016/S0140-6736(99)03287-0.
    1. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults in resource-limited settings. 2006.
    1. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006;355(19):1959–66. doi: 10.1056/NEJMoa062032.
    1. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003;187(12):1870–5. doi: 10.1086/375419.
    1. van Oosterhout JJ, Laufer MK, Graham SM, Thumba F, Perez MA, Chimbiya N, et al. A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV. J Acquir Immune Defic Syndr. 2005;39(5):626–31.
    1. Fleming TR. Evaluation of active control trials in AIDS. J Acquir Immune Defic Syndr. 1990;3(Suppl 2):S82–7.
    1. Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, et al. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr. 2009;51(1):37–46. doi: 10.1097/QAI.0b013e31819ff102.
    1. Mfutso-Bengu JM, Taylor TE. Ethical jurisdictions in biomedical research. Trends Parasitol. 2002;18(5):231–4. doi: 10.1016/S1471-4922(01)02218-8.
    1. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf. 2004;27(1):25–61. doi: 10.2165/00002018-200427010-00003.
    1. Thomson MICROMEDEX. Thomson MICROMEDEX® Healthcare series DRUGDEX® Evaluations, Copyright© 1974-2006. 2006.
    1. Pujari SN, Patel AK, Naik E, Patel KK, Dravid A, Patel JK, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr. 2004;37(5):1566–9. doi: 10.1097/00126334-200412150-00005.
    1. Marins JR, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA, et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS. 2003;17(11):1675–82. doi: 10.1097/00002030-200307250-00012.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel